XTAI4119
Market cap330mUSD
Dec 23, Last price
90.30TWD
1D
0.56%
1Q
1.69%
Jan 2017
59.57%
Name
SCI Pharmtech Inc
Chart & Performance
Profile
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and specialty chemicals. Its active pharmaceutical ingredients include Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Divalproex Sodium, Duloxetine HCl, Hydroxychloroquine sulfate, Loxoprofen Sodium, Methylphenidate HCl, Pentobarbital Sodium, Probucol, Propafenone HCl, Sodium Valproate, Thiopental, Valproic Acid, Adenine, Cannabidiol, and Dexmethylphenidate HCl. The company's intermediate products comprise Azetidin-3-ol hydrogenchloride, Diethyl Isobutyl Malonate, Diethyl dipropylmalonate, Diethyl ethyl(1-methylbutyl)malonate, Pyrogallolaldehyde, Benzhydrylamine, 1-Benzhydrylazetidin-3-ol, 1-(2-Hydroxyphenyl)-3-phenylpropan-1-one, N-Methyl-4-piperidinol, Ritalinic acid, d-Ritalinic acid HCl, (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol HCl, and (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol. Its intermediate products also consists of (S)-3-(methylmino)-1-(2-thi-enyl)propan-1-ol, (R)-3-(Methylamino)-1-phenylpropanol, (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol, Menthadienol, 5-pentylbenzene-1,3-diol Olivetol, Methyl 2,4-dihydroxy-6-pentylbenzoate, and Ethyl 2,4-dihydroxy-6-pentylbenzoate Ethyl Olivetolate. The company also provides custom manufacturing services. It sells its products in Italy, China, the United States, Germany, Taiwan, Switzerland, Spain, Japan, Netherlands, and internationally. The company was incorporated in 1987 and is based in Taoyuan City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 1,204,159 33.83% | 899,738 4.11% | 864,217 -67.86% | |||||||
Cost of revenue | 1,043,859 | 780,768 | 790,559 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 160,300 | 118,970 | 73,658 | |||||||
NOPBT Margin | 13.31% | 13.22% | 8.52% | |||||||
Operating Taxes | 69,469 | 79,040 | 9,810 | |||||||
Tax Rate | 43.34% | 66.44% | 13.32% | |||||||
NOPAT | 90,831 | 39,930 | 63,848 | |||||||
Net income | 294,721 -4.55% | 308,780 454.40% | 55,696 -84.53% | |||||||
Dividends | (23,846) | (39,743) | ||||||||
Dividend yield | 0.22% | 0.49% | ||||||||
Proceeds from repurchase of equity | 957,600 | |||||||||
BB yield | -9.03% | |||||||||
Debt | ||||||||||
Debt current | 196,946 | 112,828 | 1,584 | |||||||
Long-term debt | 850,332 | 433,574 | 2,726 | |||||||
Deferred revenue | 6,837 | 4,108 | ||||||||
Other long-term liabilities | 22,536 | 20,530 | 16,945 | |||||||
Net debt | (225,399) | 171,534 | (452,889) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 215,767 | 296,565 | 280,278 | |||||||
CAPEX | (1,029,360) | (1,167,584) | (774,981) | |||||||
Cash from investing activities | (866,203) | (1,009,087) | (539,560) | |||||||
Cash from financing activities | 1,425,665 | 547,119 | (41,516) | |||||||
FCF | (1,067,018) | (1,174,634) | (368,655) | |||||||
Balance | ||||||||||
Cash | 1,031,055 | 264,373 | 692,632 | |||||||
Long term investments | 241,622 | 110,495 | (235,433) | |||||||
Excess cash | 1,212,469 | 329,881 | 413,988 | |||||||
Stockholders' equity | 2,866,363 | 2,350,189 | 2,050,384 | |||||||
Invested Capital | 4,959,331 | 3,865,498 | 2,925,743 | |||||||
ROIC | 2.06% | 1.18% | 2.61% | |||||||
ROCE | 2.54% | 2.77% | 2.14% | |||||||
EV | ||||||||||
Common stock shares outstanding | 109,609 | 109,327 | 109,207 | |||||||
Price | 96.80 11.69% | 86.67 16.07% | 74.67 20.01% | |||||||
Market cap | 10,610,151 11.98% | 9,475,347 16.20% | 8,154,467 19.26% | |||||||
EV | 10,384,752 | 9,646,881 | 7,701,578 | |||||||
EBITDA | 305,594 | 209,582 | 137,366 | |||||||
EV/EBITDA | 33.98 | 46.03 | 56.07 | |||||||
Interest | 6,290 | 1,072 | 41 | |||||||
Interest/NOPBT | 3.92% | 0.90% | 0.06% |